This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.
Study Type
OBSERVATIONAL
Enrollment
20
Unnamed facility
Kaohisung, Taiwan
Unnamed facility
Taipei, Taiwan
Unnamed facility
Taipei, Taiwan
Progression-free survival at 6 months
Time frame: approximately 3 years
Progression-free survival
Time frame: approximately 3 years
Time to disease progression
Time frame: approximately 3 years
Duration of objective response
Time frame: approximately 3 years
Overall survival
Time frame: approximately 3 years
Safety: Incidence of adverse events
Time frame: approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.